DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report sent to investors on Sunday morning. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright dropped their price objective on DBV Technologies from $20.00 to $10.00 and set a buy rating for the company in a report on Wednesday, May 8th.

DBV Technologies Price Performance

Shares of DBV Technologies stock opened at $0.95 on Friday. The firm has a 50 day simple moving average of $1.14 and a 200 day simple moving average of $1.50. DBV Technologies has a fifty-two week low of $0.84 and a fifty-two week high of $4.08. The firm has a market cap of $91.46 million, a P/E ratio of -1.13 and a beta of 0.69.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.16. The firm had revenue of $1.41 million for the quarter, compared to analyst estimates of $3.20 million. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. On average, sell-side analysts expect that DBV Technologies will post -1.22 EPS for the current year.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 50,986 shares of the company’s stock, valued at approximately $49,000. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.